As of June 3, 2025, MediciNova Inc (MNOV) reports a ROE (Return on Equity) of -21.05%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of MediciNova Inc's ROE (Return on Equity)
Over recent years, MediciNova Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -21.05% |
| 2023-12-31 | -13.74% |
| 2022-12-31 | -20.04% |
| 2021-12-31 | -12.10% |
| 2020-12-31 | -19.42% |
This slight upward trend highlights how MediciNova Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing MediciNova Inc's ROE (Return on Equity) to Peers
To better understand MediciNova Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| MediciNova Inc (MNOV) | -21.05% |
| Trevena Inc (TRVN) | 526.17% |
| Checkpoint Therapeutics Inc (CKPT) | 445.47% |
| Abbvie Inc (ABBV) | 128.66% |
| Amgen Inc (AMGN) | 69.59% |
| Regeneron Pharmaceuticals Inc (REGN) | 15.03% |
Compared to its competitors, MediciNova Inc's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.